Clinical Trials Browser

Phase 3 × Has results × durvalumab × Clear all

NCT03875235 2026-03-19

TOPAZ-1

Phase 3 Active not recruiting

810 enrolled 24 charts 1 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase 3 Active not recruiting

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

Phase 3 Active not recruiting

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Urothelial Cancer

NCT03298451 2026-01-14

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 1 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03519971 2025-10-28

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3 Active not recruiting

328 enrolled 23 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 2 FDA

Small Cell Lung Carcinoma

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Small Cell Lung Carcinoma

NCT04712903 2025-01-07

CANTABRICO

Phase 3 Completed

101 enrolled 47 charts

Small Cell Lung Carcinoma Extensive Disease

NCT04449861 2024-11-27

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Phase 3 Completed

166 enrolled 20 charts

Small Cell Lung Carcinoma Extensive Disease

NCT04866017 2024-10-31

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Phase 3 Terminated

63 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT02454933 2024-09-19

CAURAL

Phase 3 Completed

29 enrolled 10 charts

Locally Advanced or Metastatic EGFR T790M+ NSCLC

NCT04385368 2024-08-30

MERMAID-1

Phase 3 Completed

89 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02352948 2024-07-26

ARCTIC

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT03830866 2024-07-26

CALLA

Phase 3 Completed

770 enrolled 12 charts

Locally Advanced Cervical Cancer

NCT04642469 2024-06-25

MERMAID-2

Phase 3 Completed

30 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02125461 2023-10-10

PACIFIC

Phase 3 Completed

713 enrolled 23 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03084471 2022-12-22

STRONG

Phase 3 Completed

867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT02369874 2021-02-10

EAGLE

Phase 3 Completed

736 enrolled 26 charts

Head and Neck Neoplasms, Recurrence